Exploring the action mechanism of Jinxin oral liquid on asthma by network pharmacology, molecular docking, and microRNA recognition

Jing Chen,Qiaozhen Zhu,Yanling Mo,Hao Ling,Yan Wang,Huihui Xie,Lan Li
DOI: https://doi.org/10.1097/md.0000000000035438
IF: 1.6
2024-02-10
Medicine
Abstract:Especially in children, asthma is one of the most common chronic respiratory illnesses. Approximately 8.0% of Americans reported having asthma in 2016 to 2018, including 8.1% of children under the age of 17 years. [ 1 ] Its frequency is steadily rising, particularly in emerging nations. [ 2 ] According to estimates from the World Health Organization, there are 250,000 asthma-related fatalities each year, and asthma is one of the top 20 global causes of childhood impairment. [ 3 ] Airway remodeling, airway hyperresponsiveness, and airway inflammation are the clinical signs of asthma. [ 4 , 5 ] Although the exact etiology of asthma is still unknown, gene-environment interactions are widely acknowledged to have a role in its development. [ 6 , 7 ] Despite the widespread use of bronchodilators and anti-inflammatory medications in clinical settings at this time, issues including treatment tolerance and side effects remain a major concern. Thus, there is a pressing need to create new, potent medicinal medications with fewer adverse effects. [ 8 ]
medicine, general & internal
What problem does this paper attempt to address?